This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) slid 3.04% to $425.09 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&amp;P 500 Index rising 0.13% to 7,609.78 and the Dow Jones Industrial Average rising 0.45% to 51,307.79.
This was the stock's third consecutive day of losses.
Vertex Pharmaceuticals Inc. closed 16.31% below its 52-week high of $507.92, which the company achieved on March 10th.
The stock underperformed when compared to some of its competitors Tuesday, as AbbVie Inc. (ABBV) rose 1.16% to $215.40, Krystal Biotech Inc. (KRYS) fell 1.64% to $293.21, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 1.54% to $7.65.
Trading volume (1.1 M) remained 104,626 below its 50-day average volume of 1.2 M.
Data source: Dow Jones Market Data, FactSet. Data compiled June 2, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-02-26 1638ET

VRTX

Vertex Pharmaceuticals (VRTX) shares fell 3.04% to $425.09 on Tuesday, underperforming the broader market and competitors like AbbVie despite a positive trading session. This marks the third consecutive day of losses for VRTX, which is now 16.31% below its 52-week high. Trading volume remained below the 50-day average.

MarketWatch Automated

Vertex Pharma

S&P 500

Dow Jones Industrial Average

Abbvie

Krystal Biotech

Arcturus Therapeutics

Factset Research

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors